Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Jun 3;18(1):222.
doi: 10.1186/s12967-020-02392-y.

SARS-CoV-2 SPIKE PROTEIN: an optimal immunological target for vaccines

Giovanni Salvatori  1 , Laura Luberto  1 , Mariano Maffei  2 , Luigi Aurisicchio  1   2 , Giuseppe Roscilli  1   2 , Fabio Palombo  1 , Emanuele Marra  3   4
Affiliations

SARS-CoV-2 SPIKE PROTEIN: an optimal immunological target for vaccines

Giovanni Salvatori et al. J Transl Med. .

Abstract

COVID-19 has rapidly spread all over the world, progressing into a pandemic. This situation has urgently impelled many companies and public research institutes to concentrate their efforts on research for effective therapeutics. Here, we outline the strategies and targets currently adopted in developing a vaccine against SARS-CoV-2. Based on previous evidence and experience with SARS and MERS, the primary focus has been the Spike protein, considered as the ideal target for COVID-19 immunotherapies.

Keywords: SARS-CoV-2; SPIKE protein; Vaccine.

PubMed Disclaimer

Conflict of interest statement

Laura Luberto, Mariano Maffei, Luigi Aurisicchio, Giuseppe Roscilli, Fabio Palombo and Emanuele Marra are employees at Takis Biotech and Evvivax, which are developing a vaccine against COVID-19.

References

    1. Buchholz UJ, Bukreyev A, Yang L, Lamirande EW, Murphy BR, Subbarao K, et al. Contributions of the structural proteins of severe respiratory syndrome coronavirus to protective immunity. Proc Natl Acad Sci USA. 2004;26:9804–9809. doi: 10.1073/pnas.0403492101. - DOI - PMC - PubMed
    1. Traggiai E, Becker S, Subbarao K, Kolesnikova L, Uematsu Y, Gismondo MR, et al. An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus. Nat Med. 2004;10:871–875. doi: 10.1038/nm1080. - DOI - PMC - PubMed
    1. Corti D, Zhao J, Pedotti M, Simonelli L, Agnihothram S, Fett C, et al. Prophylactic and postexposure efficacy of a potent human monoclonal antibody against MERS coronavirus. Proc Natl Acad Sci USA. 2015;112:10473–10478. doi: 10.1073/pnas.1510199112. - DOI - PMC - PubMed
    1. Walls AC, Park YJ, Tortorici MA, Wall A, McGuire AT, Veesler D. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell. 2020;180:1–12. doi: 10.1016/j.cell.2019.12.001. - DOI - PMC - PubMed
    1. Tai W, He L, Zhang X, Pu J, Voronin D, Jiang S, et al. Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine. Cell Mol Immunol. 2020 doi: 10.1038/s41423-020-0400-4. - DOI - PMC - PubMed

MeSH terms

LinkOut - more resources